医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

EdiGene Announces Publication by Company Scientific Founder in Nature Biotechnology of LEAPER™ 2.0, an Updated Version of the RNA Base Editing Technology Using Engineered Circular ADAR-recruiting RNAs

2022年02月11日 AM01:51
このエントリーをはてなブックマークに追加


 

BEIJING & CAMBRIDGE, Mass.

EdiGene, Inc., a global biotechnology company, today announced its Scientific Founder Wensheng Wei’s lab at Peking University has published a research article in Nature Biotechnology on an upgraded version of LEAPER™ (Leveraging endogenous ADAR for programmable editing of RNA) that shows significantly improved efficiency and fidelity of RNA editing in vitro and in vivo.

LEAPER™ was developed at the lab at Peking University led by Professor Wensheng Wei and was first reported in Nature Biotechnology in 2019.

“LEAPER 2.0 incorporates multiple engineered elements and significantly improves the on-target editing efficiency while reducing the bystander off-target editing events in vitro and in vivo,” Professor Wei said. “LEAPER is a powerful and versatile RNA editing technology, and our relentless research effort continues to improve its precision and efficiency to support broader applicability for therapy and basic research.”

The paper, Engineered circular ADAR-recruiting RNAs increase the efficiency and fidelity of RNA editing in vitro and in vivo in Nature Biotechnology, is available at https://www.nature.com/articles/s41587-021-01180-3.

“LEAPER™ has distinct advantages over other gene-editing technologies. With LEAPER™ 2.0, we have achieved proof of concept in multiple preclinical models through AAV delivery, and we are excited about its therapeutic potential as in vivo RNA editing therapies,” said Dong Wei, Ph.D., CEO of EdiGene. “We have built up internal capabilities both in Beijing and in Boston and formed collaborations with top research institutes to advance our lead programs, and are in discussions with potential industry partners as well to accelerate the translation of this exciting platform for patients in need worldwide.”

In November 2021, EdiGene announced separate research collaborations with the University of Wisconsin-Madison and Peking Union Medical College Hospital designed to further advance the development and translation of LEAPER™.

Both Prof. Wensheng Wei and Dr. Dong Wei will be presenting the research and therapeutic application of LEAPER™ 2.0 at the 3rd RNA Editing Summit on April 5-7, 2022 in Boston, and Dr. Dong Wei will be presenting at the 23rd annual TIDES USA Conference on May 9-12, 2022 in Boston.

About EdiGene, Inc
EdiGene is a global, clinical-stage biotechnology company focused on translating gene editing technologies into transformative therapies for patients with serious genetic diseases and cancer. The company has established its proprietary ex vivo genome-editing platforms for hematopoietic stem cells and T cells, in vivo therapeutic platform based on RNA base editing, and high-throughput genome-editing screening to discover novel targeted therapies. Founded in 2015, EdiGene is headquartered in Beijing, with offices in Guangzhou and Shanghai, China and Cambridge, Massachusetts, USA. More information can be found at www.EdiGene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220210005778/en/

CONTACT

Xiaomeng Zhang

EdiGene, Inc.

+86 10-80733899

media@edigene.com

同じカテゴリーの記事 

  • EMS Kegel Trainer BODYDOCTOR Opens New Era of Health Care Solutions in Global Femcare Market
  • EMSケーゲルトレーナー BODYDOCTOR、Femcareのグローバル市場でK-HEALTH CAREに注目が集まる
  • InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
  • METIS第3相臨床試験で主要評価項目を達成、非小細胞肺がんからの脳転移患者における頭蓋内進行までの期間を統計学的に有意に延長
  • Poxel to Report Its 2023 Annual Results by the End of April 2024